GE Diamond DNP Polarizer

描述（由申请人提供）：该S10提案旨在资助购买GE Diamond DNP偏振器，用于超极化13C药物的临床磁共振光谱成像（MRSI），该偏振器将被安置在纪念斯隆-凯特琳癌症中心的新综合代谢成像中心（CIMI）。对更精确和通用的全身分子成像技术的需求尚未得到满足，而这种手段的发展将对公共卫生产生巨大影响。超极化磁共振成像（HP- MRSI）是一种新兴的技术，具有独特的能力，可以近实时地在体内和三维成像多种代谢过程。基于临床前研究和首次使用超极化磁共振成像的临床试验的有希望的数据，预计其临床应用将对肿瘤学的许多方面产生重大影响，包括能够无创地阐明疾病机制，早期诊断疾病及其复发，以及更快地对患者进行适当的治疗方案分层。GE Diamond DNP偏光镜是第一款也是目前唯一一款用于人体的市售偏光镜。通过其在CIMI的中心安装，我们建议将钻石偏振器作为一个独特的新设施的创新中心，该设施配备了最先进的临床分子成像能力，包括集成的全身MR- pet和多核磁共振扫描仪。这将首次允许在人类患者中进行HP-MRSI/MRI/PET联合成像，使这些方法能够协同补充和交叉验证。我们已经组建了一支由基础科学和临床科室专家组成的多学科团队，成功实施了HP-MRSI，并利用HP-MRSI和HP-MRSI/MRI/PET的独特组合来针对特定的临床问题。庞大的患者群体，广泛的患者数据库，组织数据库，常规的肿瘤分子和基因组分析，以及我们临床和基础科学教师的多样性和专业知识

DESCRIPTION (provided by applicant): This S10 proposal aims at funding the purchase of a GE Diamond DNP Polarizer for clinical magnetic resonance spectroscopic imaging (MRSI) of hyperpolarized 13C agents, to be housed in the new Center for Integrated Metabolic Imaging (CIMI) at Memorial Sloan-Kettering Cancer Center. There is a great unmet need for more precise and versatile whole-body molecular imaging technologies, and the development of such means would have an enormous public-health impact. Hyperpolarized MRSI (HP- MRSI) is an emerging technology with the unique capacity to image a large variety of metabolic processes in near real-time in vivo and three-dimensionally. Based on the promising data from preclinical studies and the first clinical trial using hyperpolarized MRSI, it is expected that its clinical implementation will have a significant impact on many aspects of oncology, including the ability to elucidate disease mechanisms noninvasively, diagnose disease and its recurrence earlier, and stratify patients for appropriate treatment regimens more rapidly. The GE Diamond DNP Polarizer is the first and currently only commercially available polarizer for use in humans. Via its central installation in CIMI, we propose to make the Diamond Polarizer the nidus of innovation in a unique new facility equipped with the most cutting-edge clinical molecular imaging capabilities, including integrated whole-body MR-PET and multinuclear-capable MR scanners. This will, for the first time, allow the performance of combined HP-MRSI/MRI/PET imaging in human patients, enabling these methods to complement and cross-validate each other synergistically. We have assembled a multidisciplinary team of experts from basic science and clinical departments to successfully implement HP-MRSI and to target specific clinical questions using HP-MRSI and the unique combination of HP-MRSI/MRI/PET. Large patient populations, extensive patient databases, tissue databanks, routine molecular and genomic profiling of tumors, and the diversity and expertise of our clinical and basic science faculty will allow us to correlate the metabolic signatures identified with HP-MRSI with the molecular composition of tumors. This, in turn, will increase the chances of achieving the central goal of this application, which is to establish novel HP-MRSI biomarkers of cancer and its response to treatment.